Abstract: A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): [wherein each of R1 and R3 is independently a hydrogen atom, SO3H, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-18 arylcarbonyl group (the C1-6 alkyl group, the C1-6 alkylcarbonyl group and the C6-18 arylcarbonyl group may be optionally substituted with a halogen atom, a hydroxyl group, a C2-6 alkenyl group, a C1-6 alkoxy group, a C1-6 alkoxycarbonyl group, a C6-18 aryl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-furanyl group, a 3-furanyl group, a 2-thienyl group, a 3-thienyl group or NR9R10) , and each of R2, R4 and Ra is independently a hydrogen atom, a hydroxyl group or a C1-6 alkoxy group].

Abstract: When a stop condition is satisfied, a stop condition determination circuit (10) issues a stop instruction to an operation stop control circuit (11) to stop the operation of a functional circuit (14). A storage device (12) stores therein determination results made by the stop condition determination circuit (10) and operation conditions in the functional circuit (14). An external conveying means (13) conveys the determination results made by the stop condition determination circuit (10) to outside the semiconductor device. If these determination results are used by a peripheral device external to the semiconductor device, it is possible to prevent failures in the peripheral device and malfunctions in the system caused by faults in the semiconductor device.

Abstract: When a stop condition is satisfied, a stop condition determination circuit (10) issues a stop instruction to an operation stop control circuit (11) to stop the operation of a functional circuit (14). A storage device (12) stores therein determination results made by the stop condition determination circuit (10) and operation conditions in the functional circuit (14). An external conveying means (13) conveys the determination results made by the stop condition determination circuit (10) to outside the semiconductor device. If these determination results are used by a peripheral device external to the semiconductor device, it is possible to prevent failures in the peripheral device and malfunctions in the system caused by faults in the semiconductor device.

Abstract: A semiconductor integrated circuit is provided with one or more flip-flop circuits (10a and 10b) and a control signal generating section (20). The control signal generating section (20) outputs a control signal to control ON/OFF of the flip-flop circuits (10a and 10b). Each of the flip-flop circuits (10a and 10b) operates by receiving the clock signal and the control signal output from the control signal generating section (20).

Abstract: A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): [wherein each of R1 and R3 is independently a hydrogen atom, SO3H, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-18 arylcarbonyl group (the C1-6 alkyl group, the C1-6 alkylcarbonyl group and the C6-18 arylcarbonyl group may be optionally substituted with a halogen atom, a hydroxyl group, a C2-6 alkenyl group, a C1-6 alkoxy group, a C1-6 alkoxycarbonyl group, a C6-18 aryl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-furanyl group, a 3-furanyl group, a 2-thienyl group, a 3-thienyl group or NR9R10) , and each of R2, R4 and Ra is independently a hydrogen atom, a hydroxyl group or a C1-6 alkoxy group].

Abstract: To provide a titanium alloy which is a high-strength low-alloy with a 750 MPa or more in terms of tensile strength. A production method is capable of producing the titanium alloy by using a low-priced, low-grade sponge titanium as a raw material. This high-strength low-alloy titanium alloy has an alloy composition containing O of from 0.2 to 0.8%, C of from 0.01 to 0.15%, N of from 0.01 to 0.07%, Fe of from 0.3 to 1.0% and the balance being substantially Ti. At the time of production, a low-grade sponge Ti containing N of 0.01% or more and Fe of 0.2% or more is used in at least a portion of raw materials to allow it to be a source of the aforementioned Ni and Fe components.

Abstract: A Ti alloy for a positive electrode for electrocoagulation printing contains, as a weight percentage, 28.0 to 35.0% of Al, 0.1% or less of C, 0.05% or less of N, 0.3% or less of O, and Ti. The Ti alloy may further contain one or more elements selected from the group consisting of 0.5 to 15.0% of Nb, 0.5 to 15.0% of Ta, 0.1 to 1.0% of Hf, 0.1 to 1.0% of Zr, 1.0 to 6.0% of W, 1.0 to 6.0% of Mo, 0.5 to 6.0% of Cr, 0.5 to 6.0% of Mn, 0.5 to 6.0% of V, 0.1 to 1.0% of Si, and 0.005 to 0.10% of B, by weight. A positive electrode for electrocoagulation printing has a surface composed of a Ti alloy containing Al.

Abstract: The present invention provides a novel amino acid dysiherbaine which is a non-NMDA type glutamate receptor agonist as well as salts and biological precursors thereof, which are useful as experimental materials for elucidating neuronal death or the functions of signal transduction of the central nervous system associated with glutamate receptors and which provide a possibility for the development of a glutamate receptor blocker.A novel amino acid dysiherbaine represented by the formula (1): ##STR1## is obtained by purifying an aqueous extract of a sponge such as D. herbacea on the basis of toxicity to mice by liquid chromatography using Sephadex LH20 or the like and HPLC using a C18 column, and optionally converting it into a biological precursor thereof.

Abstract: A high strength stainless steel having a tensile strength of not less than 230 kgf/mm.sup.2 is disclosed, which comprises 0.01-0.015 st % of C and/or N, 1.0-4.0 wt % of Cu, 9.5-10.9 wt % of Ni, 12.0-17.0 wt % of Cr, 0.5-2.5 wt % of Al and/or Ti, 0.003-0.011 wt % of B, 0.02-0.2 wt % of Be and the balance of Fe, and has a temperature (Md.sub.30) of transforming 50% of austenite into martensite under a true strain of 0.3 within a range of from room temperature to -196.degree. C.

Abstract: A steel which is suitable for the material of a mold used for plastic molding and which has an improved resistance to corrosion under exposure to a halogen gas generated in injection molding of a thermoplastic synthetic resin blended with a halogen-containing flame-retarding agent is obtained by shaping a steel which consists essentially of up to 0.05% carbon, up to 1.0% silicon, up to 2.0% manganese, 5.0-8.0% nickel, 11.0-15.0% chromium, 1.0-4.0% molybdenum, 0.5-4.0% copper, 0.5-2.0% cobalt and the balance iron into a mold, and then subjecting the mold to age-hardening treatment at a temperature in the range of 400.degree.-450.degree. C. to obtain a hardness of H.sub.R C 30 or higher. The steel may further contain a small, predetermined amount of at least one machinability-improving component such as lead, tellurium, calcium and bismuth and/or a small, predetermined amount of at least one toughness or hardness-improving component such as tungsten, boron, titanium, vanadium, niobium and tantalum.